Works by Siu, Lillian L.

Results: 95
    1
    2
    3

    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.

    Published in:
    Oncologist, 2022, v. 27, n. 3, p. e286, doi. 10.1093/oncolo/oyac020
    By:
    • Wells, J Connor;
    • Sidhu, Aven;
    • Ding, Keyue;
    • Smoragiewicz, Martin;
    • Heng, Daniel Y C;
    • Shepherd, Frances A;
    • Ellis, Peter M;
    • Bradbury, Penelope A;
    • Jonker, Derek J;
    • Siu, Lillian L;
    • Gelmon, Karen A;
    • Karapetis, Christos;
    • Shapiro, Jeremy;
    • Nott, Louise;
    • O'Callaghan, Christopher J;
    • Parulekar, Wendy R;
    • Seymour, Lesley;
    • Monzon, Jose G
    Publication type:
    Article
    4
    5
    6
    7

    Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

    Published in:
    Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1
    By:
    • Rhoda Molife, L.;
    • Li Yan;
    • Vitfell-Rasmussen, Joanna;
    • Zernhelt, Adriane M.;
    • Sullivan, Daniel M.;
    • Cassier, Philippe A.;
    • Eric Chen;
    • Biondo, Andrea;
    • Tetteh, Ernestina;
    • Siu, Lillian L.;
    • Patnaik, Amita;
    • Papadopoulos, Kyriakos P.;
    • De Bono, Johann S.;
    • Tolcher, Anthony W.;
    • Minton, Susan
    Publication type:
    Article
    8
    9
    10

    Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).

    Published in:
    2021
    By:
    • Oliva, Marc;
    • Schneeberger, Pierre H. H.;
    • Rey, Victor;
    • Cho, Matthew;
    • Taylor, Rachel;
    • Hansen, Aaron R.;
    • Taylor, Kirsty;
    • Hosni, Ali;
    • Bayley, Andrew;
    • Hope, Andrew J.;
    • Bratman, Scott V.;
    • Ringash, Jolie;
    • Singh, Simron;
    • Weinreb, Ilan;
    • Perez-Ordoñez, Bayardo;
    • Chepeha, Douglas;
    • Waldron, John;
    • Xu, Wei;
    • Guttman, David;
    • Siu, Lillian L.
    Publication type:
    journal article
    11
    12
    13
    14

    Cancer patients' experiences with immune checkpoint modulators: A qualitative study.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 9, p. 3015, doi. 10.1002/cam4.2940
    By:
    • Ala‐Leppilampi, Kari;
    • Baker, Natalie A.;
    • McKillop, Chris;
    • Butler, Marcus O.;
    • Siu, Lillian L.;
    • Spreafico, Anna;
    • Abdul Razak, Albiruni R.;
    • Joshua, Anthony M.;
    • Hogg, David;
    • Bedard, Philippe L.;
    • Leighl, Natasha;
    • Oza, Amit M.;
    • Parsons, Janet A.;
    • Hansen, Aaron R.
    Publication type:
    Article
    15

    Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

    Published in:
    Cancer Medicine, 2018, v. 7, n. 11, p. 5478, doi. 10.1002/cam4.1819
    By:
    • Shepshelovich, Daniel;
    • Townsend, Amanda R.;
    • Espin‐Garcia, Osvaldo;
    • Latifovic, Lidija;
    • O'Callaghan, Chris J.;
    • Jonker, Derek J.;
    • Tu, Dongsheng;
    • Chen, Eric;
    • Morgen, Eric;
    • Price, Timothy J.;
    • Shapiro, Jeremy;
    • Siu, Lillian L.;
    • Kubo, Michiaki;
    • Dobrovic, Alexander;
    • Ratain, Mark J.;
    • Xu, Wei;
    • Mushiroda, Taisei;
    • Liu, Geoffrey
    Publication type:
    Article
    16
    17

    Additional germline findings from a tumor profiling program.

    Published in:
    BMC Medical Genomics, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s12920-018-0383-5
    By:
    • Stjepanovic, Neda;
    • Stockley, Tracy L.;
    • Bedard, Philippe L.;
    • McCuaig, Jeanna M.;
    • Aronson, Melyssa;
    • Holter, Spring;
    • Semotiuk, Kara;
    • Leighl, Natasha B.;
    • Jang, Raymond;
    • Krzyzanowska, Monika K.;
    • Oza, Amit M.;
    • Gupta, Abha;
    • Elser, Christine;
    • Ahmed, Lailah;
    • Wang, Lisa;
    • Kamel-Reid, Suzanne;
    • Siu, Lillian L.;
    • Kim, Raymond H.
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24

    A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 10, p. 2793, doi. 10.3109/10428194.2015.1018248
    By:
    • How, Jonathan;
    • Minden, Mark D.;
    • Brian, Leber;
    • Chen, Eric X.;
    • Brandwein, Joseph;
    • Schuh, Andre C.;
    • Schimmer, Aaron D.;
    • Gupta, Vikas;
    • Webster, Sheila;
    • Degelder, Tammy;
    • Haines, Patricia;
    • Stayner, Lee-Anne;
    • McGill, Shauna;
    • Wang, Lisa;
    • Piekarz, Richard;
    • Wong, Tracy;
    • Siu, Lillian L.;
    • Espinoza-Delgado, Igor;
    • Holleran, Julianne L.;
    • Egorin, Merrill J.
    Publication type:
    Article
    25
    26
    27
    28
    29

    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

    Published in:
    OncoImmunology, 2024, v. 13, n. 1, p. 1, doi. 10.1080/2162402X.2023.2290787
    By:
    • Lin, Chia-Chi;
    • Garralda, Elena;
    • Schöffski, Patrick;
    • Hong, David S.;
    • Siu, Lillian L.;
    • Martin, Miguel;
    • Maur, Michela;
    • Hui, Rina;
    • Soo, Ross A;
    • Chiu, Joanne;
    • Zhang, Tian;
    • Ma, Brigette;
    • Kyi, Chrisann;
    • Tan, Daniel SW;
    • Cassier, Philippe A.;
    • Sarantopoulos, John;
    • Weickhardt, Andrew;
    • Carvajal, Richard D.;
    • Spratlin, Jennifer;
    • Esaki, Taito
    Publication type:
    Article
    30
    31
    32
    33
    34

    Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02851-6
    By:
    • Genta, Sofia;
    • Lajkosz, Katherine;
    • Yee, Noelle R.;
    • Spiliopoulou, Pavlina;
    • Heirali, Alya;
    • Hansen, Aaron R.;
    • Siu, Lillian L.;
    • Saibil, Sam;
    • Stayner, Lee-Anne;
    • Yanekina, Maryia;
    • Sauder, Maxwell B.;
    • Keshavarzi, Sareh;
    • Salawu, Abdulazeez;
    • Vornicova, Olga;
    • Butler, Marcus O.;
    • Bedard, Philippe L.;
    • Razak, Albiruni R. Abdul;
    • Rottapel, Robert;
    • Chruscinski, Andrzej;
    • Coburn, Bryan
    Publication type:
    Article
    35

    Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.

    Published in:
    Clinical Colorectal Cancer, 2023, v. 22, n. 4, p. 457, doi. 10.1016/j.clcc.2023.08.006
    By:
    • Di Maria Jiang;
    • Parshad, Shruti;
    • Luna Zhan;
    • Hao-Wen Sim;
    • Siu, Lillian L.;
    • Liu, Geoffrey;
    • Shapiro, Jeremy D.;
    • Price, Timothy J.;
    • Jonker, Derek J.;
    • Karapetis, Christos S.;
    • Strickland, Andrew H.;
    • Wenjiang Zhang;
    • Jeffery, Mark;
    • Dongsheng Tu;
    • Ng, Siobhan;
    • Sabesan, Sabe;
    • Shannon, Jenny;
    • Townsend, Amanda;
    • O'Callaghan, Chris J.;
    • Chen, Eric X.
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43

    Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1587, doi. 10.1007/s10637-021-01141-2
    By:
    • Italiano, Antoine;
    • Miller Jr, Wilson H.;
    • Blay, Jean-Yves;
    • Gietema, Jourik A.;
    • Bang, Yung-Jue;
    • Mileshkin, Linda R.;
    • Hirte, Hal W.;
    • Higgins, Brian;
    • Blotner, Steven;
    • Nichols, Gwen L.;
    • Chen, Lin Chi;
    • Petry, Claire;
    • Yang, Qi Joy;
    • Schmitt, Christophe;
    • Jamois, Candice;
    • Siu, Lillian L.
    Publication type:
    Article
    44

    A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 6, p. 1774, doi. 10.1007/s10637-020-00928-z
    By:
    • Delord, Jean-Pierre;
    • Argilés, Guillem;
    • Fayette, Jerôme;
    • Wirth, Lori;
    • Kasper, Stefan;
    • Siena, Salvatore;
    • Mesia, Ricard;
    • Berardi, Rossana;
    • Cervantes, Andrés;
    • Dekervel, Jeroen;
    • Zhao, Sylvia;
    • Sun, Yongjian;
    • Hao, Huai-Xiang;
    • Tiedt, Ralph;
    • Vicente, Sergio;
    • Myers, Andrea;
    • Siu, Lillian L.
    Publication type:
    Article
    45

    A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

    Published in:
    Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
    By:
    • Aghajanian, Carol;
    • Bell-McGuinn, Katherine M.;
    • Burris, Howard A.;
    • Siu, Lillian L.;
    • Stayner, Lee-Ann;
    • Wheler, Jennifer J.;
    • Hong, David S.;
    • Kurkjian, Carla;
    • Pant, Shubham;
    • Santiago-Walker, Ademi;
    • Gauvin, Jennifer L.;
    • Antal, Joyce M.;
    • Opalinska, Joanna B.;
    • Morris, Shannon R.;
    • Infante, Jeffrey R.
    Publication type:
    Article
    46
    47
    48
    49
    50